Sep 19th, 2025

#AHA25 announces Late-Breaking and Featured Science

See the impressive list of science planned for presentation at Scientific Sessions 2025.

LBS.01 | Groundbreaking Trials in Cardiometabolic Therapeutics

8:30 a.m. | Saturday, Nov. 8 | Main Event 1

DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial
4391485: Olezarsen in Patients with Severe Hypertriglyceridemia: The CORE-TIMI 72a and CORE2-TIMI 72b Trials
First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV Trial

LBS.02 | Dilemmas in Antithrombotic Therapy in AFib Care Post Procedures

1:30 p.m. | Saturday, Nov. 8 | Main Event 1

Appropriate Duration of Antiplatelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug-Eluting Stents (ADAPT AF-DES)
Short Dual Antithrombotic Therapy After PCI in Patients With Atrial Fibrillation: OPTIMA-AF Trial
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy (CLOSURE-AF)
The Need for Ongoing Oral Anticoagulation in Patients With Clinical Stroke Risk Factors After Successful Catheter Ablation of Atrial Fibrillation: The OCEAN Randomized Trial

LBS.03 | Cutting-Edge Valve and Coronary Trials

3:15 p.m. | Saturday, Nov 8 | Main Event 1

Early Surgery vs. Conservative Management for Asymptomatic Severe Aortic Stenosis: Final Outcomes of the RECOVERY Trial
Biatrial vs. Left Atrial Ablation During Mitral Valve Surgery for Persistent Atrial Fibrillation in Rheumatic Heart Disease (The ABLATION Trial)
Angiography-Derived FFR-Guided Coronary Artery Bypass Grafting for Patients Undergoing Valve Surgery With Concomitant Coronary Artery Disease (FAVOR 4-QVAS): A Randomized Trial*
Liberal or Restrictive Transfusion Strategy After General and Vascular Surgery: The Transfusion Trigger After Major Operations in High Cardiac Risk Patients Trial (TOP)

LBS.04 | Cardiometabolic and Lifestyle Interventions for AFib  

8 a.m. | Sunday, Nov. 9 | Main Event 1

Dapagliflozin to Reduce Atrial Fibrillation Burden After Catheter Ablation for Atrial Fibrillation in Patients Without Diabetes or Heart Failure: The DARE-AF Randomized Clinical Trial
Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation (META-AF)
The Does Eliminating Coffee Avoid Fibrillation (DECAF) Trial

LBS.05 | Practice-Changing Trials in Blood Pressure Control 

3:30 p.m. | Sunday, Nov. 9 | Main Event 1

Oral KCl Supplementation Safely Reduces Body Na+ Surplus and Blood Pressure in Patients With Arterial Hypertension (SSTT [See Sodium To Treat])
Primary Results of the Behavioral Economics Trial to Test Effective Regulation of Blood Pressure (BETTER-BP)
DASH-Patterned Groceries Reduce Blood Pressure: Results From the GoFresh Randomized Clinical Trial (GOFRESH)
A Multifaceted Family Intervention for Blood Pressure Management in Rural China: An Open Label, Parallel Group, Cluster Randomized Trial (Healthy Family Program)

LBS.06 | Approaches to Ischemic Heart Disease Before, During and After Hospitalization

8 a.m. | Monday, Nov. 10 | Main Event 1

Prehospital Treatment With Disaggprotm (Zalunfiban) in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Final Results of the CELEBRATE Trial
Ticagrelor vs. Prasugrel in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Randomized Comparison From the TUXEDO-2 Trial
Efficacy and Safety of Extended Dual Antiplatelet Therapy in Stable Patients With Multivessel Coronary Artery Disease Undergoing Drug-Eluting Stent Implantation (DAPT-MVD): An Investigator-Initiated, Multicenter, Randomized, Open-Label, Assessor-Masked, Superiority Trial (DAPT-MVD)
Noninvasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial (CorCMR)

LBS.07 | Recipes for Success in Heart Failure

9:45 a.m. | Monday, Nov. 10 | Main Event 1

A Polypill Strategy for Heart Failure With Reduced Ejection Fraction: The POLY-HF Trial
Cardiac Allograft Vasculopathy Inhibition With AliRocumab: The CAVIAR Trial
Examining the Impact of Medically Tailored Meals vs. Produce Supplements Delivered Conditionally vs. Unconditionally on Heart Failure Readmissions and Emergency Department Visits: A Randomized Clinical Trial (FOOD-HF)
Once-Weekly Tirzepatide vs. Dulaglutide for Heart Failure Outcomes in Patients With Type 2 Diabetes, ASCVD and History of Heart Failure (Pre-Specified Analysis of the SURPASS-CVOT Randomized Clinical Trial) (SURPASS-CVOT)

LATE-BREAKING SCIENCE: FEATURED SCIENCE SESSIONS

HCMS.FS | Featured Science: HCMS

6 p.m. | Friday, Nov. 7 | Room R01

Effect of Mavacamten on Measures of Cardiopulmonary Exercise Testing: An Analysis of the ODYSSEY-HCM Randomized Trial
Polygenic Risk Enhances Penetrance and Prognosis in Hypertrophic Cardiomyopathy: Insights From a U.S.-based Multi-Ancestry Cohort
Effect of Aficamten vs. Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy (MAPLE-HCM)
Effect of Selected Baseline Characteristics and Exposure on Efficacy and Safety of Mavacamten: A Post-Hoc Analysis From the ODYSSEY Trial (ODYSSEY-HCM)

FS.01 | Arteries and Veins in Trouble: VTE and PAD

9:45 a.m. | Saturday, Nov. 8 | Room 211-213

Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: The ROXI-VTE-I and ROXI-VTE-II Trials (ROXI)
Metformin for Walking Impairment in Peripheral Artery Disease: The PERMET Randomized Clinical Trial (PERMET Trial)
The Foot-PAD Trial: A Double-Blind, Randomized Placebo-Controlled Trial to Determine the Effect of a 12-Week Program of Footplate Neuromuscular Electrical Stimulation on Walking Capacity in Patients With Peripheral Artery Disease (The FootPAD Trial)
DDCI-01 in Pulmonary Arterial Hypertension: A Multicenter Phase IIa Randomized Active-Controlled Trial (DART)
SATISFY-JP Trial: Satralizumab, an Anti-Interleukin-6 Receptor Antibody, for Pulmonary Arterial Hypertension With an Activated Immune-Responsive Phenotype: Primary Results From the Phase II Trial (SATISFY-JP)
Effect of Sotatercept on Mortality and Major Morbidity Outcomes in Patients With Pulmonary Arterial Hypertension: Pooled Analysis of the PULSAR, STELLAR and ZENITH Trials (PULSAR, STELLAR, ZENITH)
Efficacy and Safety of Imatinib Therapy Administered in Patients With Pulmonary Tumor Thrombotic Microangiopathy (PTTM): A Prospective, Multicenter Exploratory Clinical Trial (RESCUE-PTTM)

FS.02 | From Madrid to Mardi Gras: Heart Failure Trials on Parade

1:30 p.m. | Saturday, Nov. 8 | Room 211-213

Get With The Guidelines Hospital Participation and its Impact on GDMT and HF Outcomes Using an Interrupted Time Series Analysis
Efficacy and Safety of Digitoxin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DIGIT-HF (DIGIT-HF)
Clinical Responses to Aficamten Monotherapy Compared With Metoprolol for Obstructive Hypertrophic Cardiomyopathy Outcomes and Disease Burden: MAPLE-HCM Responder Analysis (MAPLE-HCM)
Blood Pressure and Symptomatic Hypotension With Dapagliflozin vs. Placebo in Patients Hospitalized With Heart Failure (DAPA ACT HF-TIMI 68)
SOTA-P-CARDIA Trial (ATRU-V): A Randomized Trial of Sotagliflozin in HFpEF Patients Without Diabetes (SOTA-P-CARDIA (ATRU-V)
Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide vs. Dulaglutide (SURPASS-CVOT)

FS.03 | Trials and Deployments of Artificial Intelligence in Cardiology

3:15 p.m. | Saturday, Nov. 8 | Room 211-213

Multicenter Clinical Study of Remote Speech Analysis to Detect Worsening Heart Failure: Results of the Pivotal DETECT-HF Trial (DETECT-HF)*
Prospective Validation and Real-World Implementation of an AI-Enabled Digital Stethoscope for Detecting Systolic Dysfunction in Low-Resource Settings. (DAMSUN-HF)
Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF
ECG Deep Learning Model Accurately Predicts Ischemic Stroke Risk (ECG2Stroke)
Accuracy of Cardiologist Reporting of Severe Aortic Stenosis and its Impact on Clinical Management: Insights From Decision-Support Artificial Intelligence Applied to 28,491 Men and Women Undergoing Echocardiography

FS.04 | Biological and Pragmatic Interventions in Heart Failure: From Present to Future

8 a.m. | Sunday, Nov. 9 | Room 211-213

ANSWER-HF: A Randomized Controlled Trial of Sacubitril/Valsartan versus Enalapril in Patients With Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction (ANSWER-HF)
Dapagliflozin Reduces Epicardial Adipose Tissue and Myocardial Fibrosis in Subclinical Heart Failure: The DAPA-EAT Trial
Effect of Aficamten vs. Metoprolol Monotherapy on Biomarkers in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Trial
First-in-Human Gene Therapy Trial for Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) MUSIC-HFpEF: Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
Safety and Efficacy of Induced Pluripotent Stem Cell-Derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure – BioVAT-HF-DZHK20 – Phase II Interim Data Report (BioVAT-HF DZHK20)
Main Results of the Cooperative Program for Implementation of Optimal Therapy in Heart Failure (COPILOT-HF) Program – A Pragmatic Randomized Study (COPILOT HF)

FS.05 | Medical and Interventional Advances in Coronary Artery Disease

9:15 a.m. | Sunday, Nov. 9 | Zone 1, Moderated Digital Posters 5

A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial
Improving Care by Faster Risk-Stratification With High-Sensitivity Point-of-Care Troponin in Patients in the Emergency Department: A Stepped-Wedge Cluster Randomised Trial (ICare-FASTER)
The Effectiveness of Heart Attack Education in Regions at Highest Risk – The Heart Matters Stepped-Wedge Randomized Control Trial (Heart Matters)
Infrared Sensor Evaluation for Noninvasive Screening and Early Triage in Acute Coronary Syndromes: The iSENSE-ACS Multicenter Study
An Individual Patient Data Meta-Analysis of Complete vs. Culprit-Lesion Only Revascularization for Acute Myocardial Infarction Involving >8,800 Individuals: The Complete Revascularization Trialists’ Collaboration (CRTC)
Long-Term Follow-up of Patients With Multivessel Coronary Artery Disease: Comparison Between Functional, Anatomical or Medical Only-Based Evaluation to Prevent Cardiovascular Events – The FAMOUS Trial
Beta-Blocker Therapy After Myocardial Infarction in Patients With Preserved Left Ventricular Ejection Fraction: An Individual Patient Data Meta-Analysis of Randomized Controlled Trials (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, CAPITAL-RCT)
Early Aspirin Withdrawal After Percutaneous Coronary Intervention in Acute Coronary Syndromes With and Without ST-Segment Elevation: Results From the NEO-MINDSET Trial

FS.06 | Pan Vascular Interventions: Anatomy and Interventions Across Various Vascular Beds

11:50 a.m. | Sunday, Nov. 9 | Zone 1, Moderated Digital Posters 5

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: A Nationwide Prospective Multicenter Registry in Japan (J-BPA)
Fractional Flow Reserve-Guided Renal Artery Stenting in Atherosclerotic Renovascular Hypertension: One-Year Results of the FAIR Randomized Trial
Coronary Angiography After Cardiac Arrest Without ST-Segment Elevation: Five-Year Outcomes (COACT)
Prospective, Multicenter, Open-Label, Randomized Controlled Trial of Deferred Stenting vs. Prompt Stenting in Acute Occlusion of Left Main Coronary Artery: Primary Outcomes of the OPTIMAL Trial*
Coronary CT Angiography in Prediction of Coronary Events (SCAPIS)*
Coronary CT Angiography Plaque as a Predictor of Death, Cardiovascular Death and Myocardial Infarction (MUSHY PEAS)
Risk Stratification by AI-Guided CT Coronary Atherosclerosis Quantification Alongside the Clinical Likelihood of Obstructive Stenosis (CONFIRM2)

FS.07 | Emerging Opportunities for Managing Cardiometabolic Syndrome

3:15 p.m. | Sunday, Nov. 9 | Zone 1, Moderated Digital Posters 5

Arterial Stiffness Mechanisms and Orthostatic Hypotension in the Systolic Blood Pressure Intervention Trial (SPRINT)
KARDIA-3: A Randomized Trial of Zilebesiran vs. Placebo on Top of Standard Care for Patients With Hypertension and Established Cardiovascular Disease or High Cardiovascular Risk With or Without Chronic Kidney Disease (KARDIA-3)
Effect of Baxdrostat on 24-Hour Average Ambulatory Blood Pressure in Patients With Resistant Hypertension: The Bax24 Trial
Once-Weekly Tirzepatide vs. Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Established Cardiovascular Disease (SURPASS-CVOT)
Cardiovascular Outcomes for Tirzepatide and Semaglutide: A RCT-DUPLICATE Initiative (TIRZSEMA-CVOT)
Enlicitide, an Oral PCSK9 Inhibitor, in Participants With Heterozygous Familial Hypercholesterolemia: A Double-Blind, Phase 3, Randomized Placebo-Controlled Trial (CORALreef HeFH)
Long-Term Efficacy and Safety of Lerodalcibep in the Open-Label 72-Week Extension Study of Subjects Previously on Inclisiran or Lerodalcibep in the LIBerate-VI Trial (LIBerate-OLE)
Lifestyle Intervention for Sustained Remission of Metabolic Syndrome (ELM: Enhanced Lifestyles in the Metabolic Syndrome)

FS.08 | Featured Science in EP

8 a.m. | Monday, Nov. 10 | Room 211-213

Pulsed Field Ablation vs. Sham Ablation to Treat Atrial Fibrillation (The PFA-SHAM Trial)
MANIFEST-US: Multicenter Study on the Safety of Pulsed Field Ablation in the United States (MANIFEST-US)
Strength-Based Exercise Is Not Associated With Risk of Ventricular Arrhythmia in Arrhythmogenic Cardiomyopathy – Toward Safer Exercise Options
Artificial Intelligence Analysis of the 12-Lead ECG and Clinical Factors to Predict Out-of-Hospital Cardiac Arrest
Primary Results From the Post Approval Study of a Next-Generation Wearable Cardioverter Defibrillator System: The ACE-PAS Trial
Efficacy and Safety of Flecainide Compared to Amiodarone for Atrial Fibrillation Cardioversion in Patients With Coronary Artery Disease and Preserved Ejection Fraction – FLECA-ED Trial

FS.09 | Influenza and COVID Science

1:30 p.m. | Monday, Nov. 10 | Room 243

High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes: The FLUNITY-HD Pooled Analysis
Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights From the KP VACCINATE Megatrial
Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals With and Without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis (DAN-GAL-FLU (DANFLU-2 and GALFLU))
Influenza Vaccination and Risk of Cardiovascular Events: An Instrumental Variable Analysis of >600,000 Participants From the NUDGE-FLU-CHRONIC 1 and 2 Trials
Resistance Exercise Therapy After COVID-19 Infection: A Randomized, Controlled Trial (CISCO-21)

FS.10 | Rewriting the Code for Cardiac Amyloid: Novel Identification, Treatment and Cure

1:30 | Monday, Nov. 10 | Room 211-213

Artificial Intelligence-Based Software for Checking Real-World Echocardiography to Identify Hidden Cardiac Amyloidosis: AI-SCREEN-CA
Improving Detection of Transthyretin Cardiac Amyloidosis With AI: A Single-Arm Multicenter Trial
Primary Results From the Phase 2 Randomized, Placebo Controlled, Blinded Trial of the Monoclonal Antibody Coramitug in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)*
Updated Phase 1 Clinical Trial Outcomes of CRISPR Gene Editing With Nexiguran Ziclumeran In Patients With Transthyretin Amyloidosis With Cardiomyopathy

FS.11 | Lipid Therapies: Translation to Implementation

3:15 p.m. | Monday, Nov. 10 | Room 211-213

SHR-1918, an Angiopoietin-Like 3 Antibody, in Patients With Suboptimally Controlled Hyperlipidemia
Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels After Single-Dose of Kylo-11, a LPA-Targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study
Evolocumab and Saphenous Vein Graft Patency Following Coronary Artery Bypass Graft (CABG) Surgery in People With and Without Diabetes: A Pre-Specified Analysis of the Randomized Placebo Controlled NEWTON-CABG CardioLink-5 Trial
Effects of Real-Time Notification of AI-Derived Incidental Coronary Artery Calcium on Statin Initiation: The NOTIFY-PICTURE Trial
A Novel Approach to Manage Hypercholesterolemia: The Veterans Affairs Lipid Optimization Reimagined Quality Improvement (VALOR-QI) Program
Refining ASCVD Risk Stratification Using a Lipid-Derived Index: Multicohort Evidence Beyond Guideline Thresholds

LATE-BREAKING SCIENCE IN MAIN EVENTS

HF.ME.01 | Forgotten No More: The Current Belle of the Ball? Breakthrough Evolutions in Hypertrophic Cardiomyopathy

9:45 AM | Saturday, Nov. 8 | Main Event II

TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data From MyPEAK-1, a Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201 in Adult Patients With MYBPC3-Associated Hypertrophic Cardiomyopathy (TN-201 MyPEAK Study)

PL.ME.02 | Shifting Paradigms in Lipid Management for ASCVD Risk

1:30 p.m. | Saturday, Nov. 8 | Main Event 2

Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults With or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial

OTHER WAYS TO VIEW LATE-BREAKING SCIENCE

IntSym.02 | Circulating Global Health Knowledge: Key Findings From AHA Journals

2 p.m. | Friday, Nov. 7 | Room 243

Worldwide Patterns for Premature Atherosclerotic Cardiovascular Disease: A Meta-Analysis

IntSym.03 | Advances in Global Health Research: Opportunities and Challenges

4 p.m. | Friday, Nov. 7 | Room 243

Deep Learning Derived Coronary Artery Calcium From Retinal Images for Prediction of Cardiovascular Disease in Two Different Cohorts: Multi-Ethnic Study of Atherosclerosis (MESA) and Rotterdam Study (MERO)
Contrasting the Hemodynamic Profile vs. Health Service Burden of 1.2 Million Men and Women With Aortic Stenosis (2010-21): New Insights From the National Echo Database of Australia

PL.CVS.08 | The AHA Health Care by Food Initiative Is Bearing Fruits: Early Results From the AHA Food is Medicine Pilot Projects

3:15 p.m. | Monday, Nov. 10 | Room 220-222